

29 January 2025

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

BEXIMCO PHARMACEUTICALS LIMITED

Half Year Results 2024-25

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.:213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces its unaudited financial results for the six months ended 31 December 2024.

Financial Highlights

Half year financial highlights

- Net sales increased 8.8% to Bangladesh Taka ("BDT") 24,013.4m/£ 161.5m (2023-24: BDT22,063.6m / £ 157.7m)
 - Domestic sales increased 7.4% to BDT 22,262.3m / £ 149.7m (2023-24: BDT 20,733.4m / £148.2m)
 - Export sales increased 31.6% to BDT 1,751.1m / £ 11.8m (2023-24: BDT 1,330.2m / £9.5m)
- Profit after tax increased 17.5% to BDT 3,535.0m/£ 23.8m (2023-24: BDT 3,008.2m / £21.5m)

Second quarter financial highlights

- Net sales increased 12.8% to BDT 12,299.6m / £ 82.7m (2023-24: BDT 10,904.2m / £77.9m)
- Profit after tax increased 27.9% to BDT 1,843.1m / £ 12.4m (2023-24: BDT 1,440.8m / £10.3m)

Operational highlights

- Launched four new products in Bangladesh market
- Completed 28 new registrations of 27 products across 5 countries
- Commenced export to four new countries - Cuba, Malta, Qatar and Angola

Beximco Pharma Managing Director, Iqbal Ahmed, commented:

"We're pleased to announce Beximco Pharma's second quarter and half year results today, demonstrating strong, profitable growth despite persisting macro-economic challenges. We have launched four new products domestically while we have experienced further growth internationally through new product registrations and expansion into new export countries. We look forward to building on this momentum into the second half of the year and continue to provide vital medicine to patients across the world."

The half yearly accounts can be viewed at the Company's website: www.beximcopharma.com

(Exchange rates of £1=Taka 148.6917 for 31 December 2024 and £1=Taka 139.9145 for 31 December 2023 have been used in this announcement.)

This announcement is available in its entirety at http://www.ms-pdf.londonstockexchange.com/ms/0191V_1-2025-1-28.pdf

For further information please visit www.beximcopharma.com or enquire to:

Beximco Pharma

S M Rabbur Reza, Chief Operating Officer
Tel: +880 2 58611001, Ext. 20111

Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext. 20030

Mohammad Asad Ullah, FCS
Executive Director & Company Secretary
Tel: +880 2 41060531, Ext. 10140

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555

SP Angel Corporate Finance LLP (Broker)

Matthew Johnson
Tel: +44 (0) 20 3470 0470

FTI Consulting

Simon Conway / Victoria Foster Mitchell / Sam Purewal
Tel: +44 (0)20 3727 1000

Notes to Editors

About Beximco Pharmaceuticals Limited

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6,000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IR BPMRTMTTTBIA